Center Serial # CV3153-2



Post Test, Evaluation, and Credit Application Form

Pulmonary Arterial Hypertension: Knowing the Current Therapeutic Options Webcast On Demand

Release Date: March 18, 2013 Credit Expiration Date: March 18, 2014 ACPE UAN: 0473-9999-13-002-H01-P

INSTRUCTIONS FOR CREDIT

- 1. Review the entire CE information including target audience, learning objectives, and disclosures.
- 2. Review each episode.
- 3. Complete the Post Test, Evaluation, and Credit Application Form.
- 4. Please note that in order to receive credit you must achieve a score of at least 70%.
- 5. Mail the completed Post Test, Evaluation, and Credit Application Form to Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807 or

Fax to (908) 235-4222 or

Email to bhassid@vemcomeded.com.

6. The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit <u>http://www.nabp.net/</u>.

CREDIT APPLICATION (Please Print Clearly)

Name and Degree (please write clearly)				
Practice Setting				
Address				
City	State Zip			
Country	Phone Number			
E-mail				
NABP e-Profile ID	Date of Birth (in MMDD format)			
I certify that I participated in Pulmonary Arterial Hypertension: Knowing the Current Therapeutic Options				
Signature	Date			

Name:_____

OST TEST (Please select the most appropriate answer)				
1. Pulmonary arterial hypertension is defined as having a mean pulmonary arterial pressure (mPAP) of:				
$\square > 10 \text{ mmHg} \qquad \square > 25 \text{mmHg} \qquad \square > 40 \text{ mmHg} \qquad \square > 60 \text{ mmHg}$				
Current PAH therapy targets all of the following pathways except:				
□ Vasoactive intestinal peptide (VIP) □ Endothelin □ Nitric Oxide □ Prostacyclin				
All of the following is specifically recommended for patients with PAH except:				
□ Encouraging exercise and activity within the limits of disease □ Immunizations				
□ High-dose vitamin E □ Contraception				
Approximately what percent of idiopathic PAH patients will respond to calcium-channel blocker therapy?				
$\Box 15\%$ $\Box 30\%$				
The therapeutic target of epoprostenol is within the:				
□ Endothelin pathway □ Prostacyclin pathway □ Glutathione pathway □ Nitric oxide pathway				
The therapeutic target of bosentan is within the:				
□ Endothelin pathway □ Prostacyclin pathway □ Glutathione pathway □ Nitric oxide pathway				
Epoprostenol administration requires the use of a central venous catheter and a continuous infusion pump?				
□ True				
□ False				
Treprostinil is available in all of the following formulations except:				
 Intravenous Subcutaneous 				
□ Inhaled				
9. The use of nitrates is contraindicated in patients receiving a phosphodiesterase type 5 (PDE-5) inhibitor.				
□ True				
□ False				
10. All of the following are prostacyclin infusion safety considerations except:				
□ Pump should never be stopped or turned off				
$\square \text{ Never flush or prime the line}$				
 Therapy can be infused with other medications The pumps are not compatible with X-rays 				

Name:_____

FACULTY: Please rate overall faculty effectiveness and subject matter expertise.	1 Fair	2	3	4	5 Excellent	
Heather R. Bream-Rouwenhorst, PharmD, BCPS						
Teaching Ability						
Knowledge and expertise in the subject						
James C. Coons, PharmD, BCPS (AQ Cardiology)						
Teaching Ability						
Knowledge and expertise in the subject						
Rebekah L. Hanson, PharmD, BCPS, BCACP						
Teaching Ability						
Knowledge and expertise in the subject						
Roberto F. Machado, MD						
Teaching Ability						
Knowledge and expertise in the subject						
Comments:						

LEARNING OBJECTIVES: Please rate if the Learning Objectives were met.	1 Disagree	2	3	4	5 Agree
Discuss the pathophysiology of PAH					
Compare the safety and efficacy among the various classes of medications used in the treatment of PAH					
Utilize evidence-based guidelines to select appropriate therapy to meet individualized patient treatment goals					
If you answered "Disagree" to any objective, please explai	n.				

Name:_

OVERALL EVALUATION	1 Disagree	2	3	4	5 Agree
The content was relevant to my practice and educational needs.					
The educational format was effective and encouraged learning					
Printable course material was helpful					
The activity was fair, balanced, and without commercial bias.					
If you faal that the material was NOT presented in a fair and balanced manner places evolain further					

If you feel that the material was NOT presented in a fair and balanced manner, please explain further.

Types of online learning/format you prefer?

COMMITMENT TO CHANGE

As an accredited provider of continuing education, we are asking our learners to reflect on how they might alter their practices as a result of participating in CME/CPE activities. The request below solicits your commitment to change based on what you have learned. We hope that you will find this exercise useful and thank you in advance for participating.

- **1.** Based on your participation in this activity, do you plan to make any changes in your professional practice?
 - □ Yes □ No

2. Please describe the changes you plan to implement:

3. What are the barriers you anticipate that may impact implementation of these changes?

DO YOU HAVE (1) ANY SUGGESTIONS FOR IMPROVING THIS ACTIVITY OR (2) COMMENTS?